Tecvayli

News

J&J says 2026 sales could top $100 billion

J&J says its sales should top $100 billion this year, as it pushes its oncology business towards a target of $50 billion by the end of the decade.

News

J&J builds case for earlier Tecvayli use in multiple myeloma

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.

News

J&J claims FDA's latest national priority voucher

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

News

J&J says two drugs are better than one in pretreated myeloma

Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.

News

NICE updates on controversial multiple myeloma decisions

NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether.

News

Regeneron set for August FDA decision on BCMA bispecific

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin

J&J says 2026 sales could top $100 billion

J&J builds case for earlier Tecvayli use in multiple myeloma

J&J claims FDA's latest national priority voucher

J&J says two drugs are better than one in pretreated myeloma

NICE updates on controversial multiple myeloma decisions

Regeneron set for August FDA decision on BCMA bispecific

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Tecvayli

Editor's Picks